Development of the predictor hERG fluorescence polarization assay using a membrane protein enrichment approach

Assay and Drug Development Technologies

Volumn 6, Issue 2, 2008, Pages 213-223

  Piper, David R ^a   Duff, Steve R ^b   Eliason, Hildegard C ^a   Frazee, W Jack ^a   Frey, Elizabeth A ^a   Fuerstenau Sharp, Maya ^a   Jachec, Christine ^a   Marks, Bryan D ^a   Pollok, Brian A ^a   Shekhani, Mohammed Saleh ^c   Thompson, David V ^a   Whitney, Pam ^a   Vogel, Kurt W ^a   Hess, Stephen D ^a  

^a INVITROGEN CORPORATION   (United States)

^b Pharmaceutical Product Development   (United States)

^c Centrose ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMITRIPTYLINE; ASTEMIZOLE; BEPRIDIL; DOFETILIDE; FLUOXETINE; HALOPERIDOL; MEMBRANE PROTEIN; PIMOZIDE; POTASSIUM CHANNEL HERG; TERFENADINE; THIORIDAZINE;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE POLARIZATION; HUMAN; HUMAN CELL; LIGAND BINDING; PATCH CLAMP; PROTEIN EXPRESSION;

ANTIGENS, CD8; CELL LINE; CELL MEMBRANE; DATA INTERPRETATION, STATISTICAL; DRUG EVALUATION, PRECLINICAL; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; FLOW CYTOMETRY; FLUORESCENCE POLARIZATION; FLUORESCENT DYES; GENETIC ENGINEERING; HUMANS; IMMUNOHISTOCHEMISTRY; MEMBRANE POTENTIALS; MEMBRANE PROTEINS; PATCH-CLAMP TECHNIQUES; RADIOLIGAND ASSAY;

EID: 43449090973     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2008.137     Document Type: Article

References (33)

1. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
2. Sanguinetti MC, Jiang C, Curran ME, Keating MT: A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell 1995;81:299-307.
3. Trudeau MC, Warmke JW, Ganetzky B, Robertson GA: HERG, a human inward rectifier in the voltage-gated potassium channel family. Science 1995;269:92-95.
4. Warmke JW, Ganetzky B: A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci U S A 1994;91:3438-3442.
5. Sanguinetti MC, Tristani-Firouzi M: hERG potassium channels and cardiac arrhythmia. Nature 2006;440:463-469.
6. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, et al.: The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000;21:1216-1231.
7. + channel blockers. J Med Chem 2002;45:3844-3853.
8. Bode G, Olejniczak K: ICH topic: the draft ICH S7B step 2: note for guidance on safety pharmacology studies for human pharmaceuticals. Fundam Clin Pharmacol 2002;16:105-118.
9. Bridgland-Taylor MH, Hargreaves AC, Easter A, Orme A, Henthorn DC, Ding M, et al.: Optimisation and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J Pharmacol Toxicol Methods 2006;54:189-199.
10. Dubin AE, Nasser N, Rohrbacher J, Hermans AN, Marrannes R, Grantham C, et al.: Identifying modulators of hERG channel activity using the PatchXpress planar patch clamp. J Biomol Screen 2005;10:168-181.
11. Whitebread S, Hamon J, Bojanic D, Urban L: Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discov Today 2005;10:1421-1433.
12. o. J Pharmacol Toxicol Methods 2004;50:187-199.
13. 3H]Dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen. Eur J Pharmacol 2001;430:147-148.
14. + channels. J Pharmacol Sci 2004;95:311-319.
15. Wang J, Della Penna K, Wang H, Karczewski J, Connolly TM, Koblan KS, et al.: Functional and pharmacological properties of canine ERG potassium channels. Am J Physiol Heart Circ Physiol 2003;284:H256-H267.
16. Burke TJ, Loniello KR, Beebe JA, Ervin KM: Development and application of fluorescence polarization assays in drug discovery. Comb Chem High Throughput Screen 2003;6:183-194.
17. Huang X: Fluorescence polarization competition assay: the range of resolvable inhibitor potency is limited by the affinity of the fluorescent ligand. J Biomol Screen 2003;8:34-38.
18. Banks P, Gosselin M, Prystay L: Impact of a red-shifted dye label for high throughput fluorescence polarization assays of G protein-coupled receptors. J Biomol Screen 2000;5:329-334.
19. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, et al.: Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 1998;74:230-241.
20. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ: Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 1981;391:85-100.
21. Singleton DH, Boyd H, Steidl-Nichols JV, Deacon M, Groot MJ, Price D, et al.: Fluorescently labeled analogues of dofetilide as high-affinity fluorescence polarization ligands for the human ether-a-go-go-related gene (hERG) channel. J Med Chem 2007;50:2931-2941.
22. + channel? Eur J Pharmacol 2001;412:203-212.
23. + channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 1998;54:695-703.
24. Kongsamut S, Kang J, Chen XL, Roehr J, Rampe D: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 2002;450:37-41.
25. Snyders DJ, Chaudhary A: High affinity open channel block by dofetilide of HERG expressed in a human cell line. Mol Pharmacol 1996;49:949-955.
26. Tie H, Walker BD, Valenzuela SM, Breit SN, Campbell TJ: The heart of psychotropic drug therapy. Lancet 2000;355:1825.
27. Zhang JH, Chung TD, Oldenberg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
28. Deacon M, Singleton D, Szalkai N, Pasieczny R, Peacock C, Price D, et al.: Early evaluation of compound QT prolongation effects: a predictive 384-well fluorescence polarization binding assay for measuring hERG blockade. J Pharmacol Toxicol Methods 2007;55:238-247.
29. Jurman ME, Boland LM, Liu Y, Yellen G: Visual identification of individual transfected cells for electrophysiology using antibody-coated beads. Biotechniques 1994;17:876-881.
30. Murphy SM, Palmer M, Poole MF, Padegimas L, Hunady K, Danzig J, et al.: Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel. J Pharmacol Toxicol Methods 2006;54:42-55.
31. + channels by cultivation at reduced temperature. BMC Biotechnol 2007;7:93.
32. rd, Baskin EP, Beare CM, Appleby SD, et al.: Cardiac electrophysiologic and antiarrhythmic actions of two long-acting spirobenzopyran piperidine class III agents, L-702,958 and L-706,000 [MK-499]. J Pharmacol Exp Ther 1994;269:541-554.
33. Gintant GA, Su Z, Martin RL, Cox BF: Utility of hERG assays as surrogate markers of delayed cardiac repolarization and QT safety. Toxicol Pathol 2006;34:81-90.